These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19306894)

  • 1. Target site occupancy: emerging generalizations from clinical and preclinical studies.
    Grimwood S; Hartig PR
    Pharmacol Ther; 2009 Jun; 122(3):281-301. PubMed ID: 19306894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Principles of pharmacodynamics and their applications in veterinary pharmacology.
    Lees P; Cunningham FM; Elliott J
    J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Receptor occupancy and antipsychotic drug action measured by PET and SPECT].
    Okubo Y; Suhara T
    Seishin Shinkeigaku Zasshi; 2001; 103(4):329-40. PubMed ID: 11392846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cocaine abuse and sensitization of striatal dopamine transmission: a critical review of the preclinical and clinical imaging literature.
    Narendran R; Martinez D
    Synapse; 2008 Nov; 62(11):851-69. PubMed ID: 18720516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
    Hancock AA
    Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417.
    Scott-Stevens P; Atack JR; Sohal B; Worboys P
    Biopharm Drug Dispos; 2005 Jan; 26(1):13-20. PubMed ID: 15578749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NMDA receptor complex: a long and winding road to therapeutics.
    Wood PL
    IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using positron emission tomography to facilitate CNS drug development.
    Lee CM; Farde L
    Trends Pharmacol Sci; 2006 Jun; 27(6):310-6. PubMed ID: 16678917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy.
    Maier DL; Sobotka-Briner C; Ding M; Powell ME; Jiang Q; Hill G; Heys JR; Elmore CS; Pierson ME; Mrzljak L
    J Pharmacol Exp Ther; 2009 Jul; 330(1):342-51. PubMed ID: 19401496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpretation of treatment results with biological agents: is there a need for a new methodology?
    Begent RH
    J BUON; 2007 Sep; 12 Suppl 1():S53-8. PubMed ID: 17935278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs and their molecular targets: an updated overview.
    Landry Y; Gies JP
    Fundam Clin Pharmacol; 2008 Feb; 22(1):1-18. PubMed ID: 18251718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulus amplification, efficacy, and the operational model. Part II--ternary complex occupancy mechanisms.
    Trzeciakowski JP
    J Theor Biol; 1999 Jun; 198(3):347-74. PubMed ID: 10366491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assay technologies for screening ion channel targets.
    Mattheakis LC; Savchenko A
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):124-34. PubMed ID: 11727318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate- and GABA-based CNS therapeutics.
    Foster AC; Kemp JA
    Curr Opin Pharmacol; 2006 Feb; 6(1):7-17. PubMed ID: 16377242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of constitutive G protein-coupled receptor activity for drug discovery.
    Chen G; Way J; Armour S; Watson C; Queen K; Jayawickreme CK; Chen WJ; Kenakin T
    Mol Pharmacol; 2000 Jan; 57(1):125-34. PubMed ID: 10617687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.